scholarly journals Endoscopic ultrasonography‐guided ethanol ablation of pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 disease following complicated total pancreatectomy

2019 ◽  
Vol 7 (2) ◽  
pp. 97-101
Author(s):  
Hsiang‐Hung Lin ◽  
Chen‐Wang Chang ◽  
Ming‐Jen Chen
Keyword(s):  
Neuroendocrine Tumors ◽  
Endoscopic Ultrasonography ◽  
Multiple Endocrine Neoplasia ◽  
Multiple Endocrine Neoplasia Type ◽  
Total Pancreatectomy ◽  
Pancreatic Neuroendocrine Tumors ◽  
Ethanol Ablation ◽  
Endocrine Neoplasia ◽  
Endocrine Neoplasia Type

scholarly journals Octreotide Use in a Patient with MEN-1 Syndrome and Multifocal Pancreatic Neuroendocrine Tumors: A Case Report and Review of the Literature

2019 ◽  
Vol 2019 ◽  
pp. 1-6 ◽  
Author(s):  
Matthew H. Kemm ◽  
Cory D. Manly ◽  
Thanh D. Hoang ◽  
Vinh Q. Mai ◽  
Mohamed K. M. Shakir
Keyword(s):  
Neuroendocrine Tumors ◽  
Pancreatic Polypeptide ◽  
Multiple Endocrine Neoplasia ◽  
Multiple Endocrine Neoplasia Type ◽  
Pancreatic Neuroendocrine Tumors ◽  
Significant Drop ◽  
Endocrine Neoplasia ◽  
Endocrine Neoplasia Type ◽  
Octreotide Therapy

We report a patient with multiple endocrine neoplasia type 1 with pancreatic polypeptide (PP) secreting subcentimeter pancreatic neuroendocrine tumors (pNETs) treated with octreotide and review the current literature that pertains to the management of these patients. Clinical data, laboratory results, and imaging were reviewed. A literature search was performed in PUBMED using combinations of the terms “multiple endocrine neoplasia type 1,” “somatostatin,” octreotide,” “pancreatic polypeptide,” and “pancreatic tumor.” Relevant references were selected and reviewed. A 43-year-old male with a history of MEN1 and multiple subcentimeter neuroendocrine tumors with elevation of PP was treated with octreotide therapy leading to a reduction and normalization of PP levels. The patient tolerated octreotide therapy but self-discontinued octreotide after 24 months with a rise in PP levels off therapy. Tumors remained stable in size through 40 months of imaging follow-up. In patients with MEN1 and subcentimeter pNETs, octreotide therapy is well tolerated and can lead to a significant drop in PP levels with no change in lesion size. There is insufficient data to suggest long-term benefit with octreotide therapy but it may be considered versus standard conservative management.

Sign in / Sign up

Export Citation Format

Share Document